GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (NAS:FBIO) » Definitions » Pretax Margin %

Fortress Biotech (Fortress Biotech) Pretax Margin % : -143.41% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Fortress Biotech Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Fortress Biotech's Pre-Tax Income for the three months ended in Dec. 2023 was $-28.61 Mil. Fortress Biotech's Revenue for the three months ended in Dec. 2023 was $19.95 Mil. Therefore, Fortress Biotech's pretax margin for the quarter that ended in Dec. 2023 was -143.41%.

The historical rank and industry rank for Fortress Biotech's Pretax Margin % or its related term are showing as below:

FBIO' s Pretax Margin % Range Over the Past 10 Years
Min: -6243.68   Med: -281.83   Max: -181.79
Current: -181.79


FBIO's Pretax Margin % is ranked worse than
50.63% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs FBIO: -181.79

Fortress Biotech Pretax Margin % Historical Data

The historical data trend for Fortress Biotech's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Pretax Margin % Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -277.54 -225.55 -238.92 -281.83 -181.79

Fortress Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -347.45 -443.68 -341.08 -30.45 -143.41

Competitive Comparison of Fortress Biotech's Pretax Margin %

For the Biotechnology subindustry, Fortress Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Pretax Margin % falls into.



Fortress Biotech Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Fortress Biotech's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-153.633/84.513
=-181.79 %

Fortress Biotech's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-28.605/19.946
=-143.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortress Biotech  (NAS:FBIO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Fortress Biotech Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (Fortress Biotech) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
Executives
Rosenwald Lindsay A Md director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN 375 PARK AVE, NEW YORK NY 10152
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
David Jin officer: Chief Financial Officer C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036
Dov Klein director C/O FORTRESS BIOTECH, INC., 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Robyn Hunter officer: Chief Financial Officer 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eric K Rowinsky director IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Malcolm Hoenlein director 750 LEXINGTON AVENUE, NEW YORK NY 10022
Michael S Weiss director, 10 percent owner, officer: EXECUTIVE VICE CHAIRMAN 750 LEXINGTON AVE, NEW YORK NY 10022
J Jay Lobell director 365 W END AVE, APARTMENT 10A, NEW YORK NY 10024
Jimmie Harvey director 3741 EAST FAIRWAY DRIVE, BIRMINGHAM AL 35213
Kevin Lorenz director C/O NUVEEN, 333 W. WACKER DR., CHICAGO IL 60606
George Avgerinos officer: SVP, Biologics Operations C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Kevin Horgan other: Former Chief Medical Officer C/O SOLIGENIX, INC., 29 EMMONS DRIVE, STE. C-10, PRINCETON NJ 08540
David Jonathan Barrett director ONE PENN PLAZA, SUITE 2514, NEW YORK NY 10119
Harlan F Weisman director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803

Fortress Biotech (Fortress Biotech) Headlines

From GuruFocus